Ilaris

This page shows the latest Ilaris news and features for those working in and with pharma, biotech and healthcare.

Novartis withdraws EU filing for canakinumab

The decision is a further setback for this expansion in the use of canakinumab, which Novartis already markets as an inflammatory disease treatment under the brand name Ilaris.

Latest news

Novartis culls pipeline to focus on most transformative science

It recently hit problems with one of its most important late-stage programmes when the FDA refused to accept the filing of anti-inflammatory drug canakinumab (Ilaris) in cardiovascular risk reduction.
Daily Brief: EULAR kicks off, Brexit lurches closer and Autolus prepares for IPO

On today’s agenda expect new trial data from Novartis' Ilaris in gout, Lilly's Oluminant in systemic lupus and AbbVie's new JAK inhibitor upadacitinib.
CV data sets up Novartis' Ilaris for blockbuster sales

Drug shown to reduce major adverse cardiovascular events. Novartis has posted surprise phase III data that could transform the fortunes of its anti-inflammatory drug Ilaris, making it an option to ... The CANTOS study showed that the active ingredient in
Novartis' Ilaris wins three new FDA approvals

Immunotherapeutic expands in rare Periodic Fever Syndrome conditions. Novartis' anti-inflammatory therapy Ilaris (canakinumab) has received new US approvals for its use in three rare Periodic Fever Syndrome conditions. ... Paul Hudson, Novartis
Novartis wins childhood arthritis indication for Ilaris in EU

Novartis' inflammatory disease drug Ilaris (canakinumab) can be used more widely in the EU following its approval for the treatment of a rare form of childhood arthritis. ... The European Commission (EC) gave its final assent to Ilaris for the treatment

More from news
Approximately 4 fully matching, plus 9 partially matching documents found.

Latest appointments

AIMM Therapeutics appoints former Novartis VP Jan de Vries as CEO

During his time at Novartis, de Vries led the discovery and early development of several drugs including Elidel (pimecrolimus) for eczema, Ilaris (canakunimab) for cryopyrin-associated periodic syndromes, Gilenya (fingolimod) for

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Account Director – London based Medical Communications Agency: Excellent Remuneration Package

FREELANCE Medical Writer (Initial 2/ 3 months term) - London Off...: Excellent Daily Rate

Senior Account Executive – Account Manager – Healthcare Advertis...: £32000 - £43000 Bonus Benfits

Account Director – UK Office: Excellent salary and benefits

Account Director, Healthcare Communications: Salary TBC

Strategic Planner, Healthcare Advertising Agency: Salary TBC

Senior Medical Writer, Healthcare Advertising Agency: £45, 000 – £50, 000

Account Director - Healthcare Advertising - London - 2 DAYS HOME...: £50000 - £70000

Senior Account Manager > Account Director - London - Medical ...: Salary TBC

Account Director - Medical Communications - London / South East: Excellent Salary and Benefits on offer

FREELANCE Account Director – Healthcare Advertising – London – 3...: Competitive Daily Rates

Subscribe to our email news alerts

PMHub

Add my company

Wordbird

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

The relevance of patient perspectives to value: Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?: Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
The evolution of real-world studies: How industry and regulators are using real-world data...